Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
In the latest session, Idexx Laboratories, Inc (NASDAQ: IDXX) closed at $725.93 down -0.93% from its previous closing price of $732.73. In other words, the price has decreased by -$0.93 from its previous closing price. On the day, 0.5 million shares were traded. IDXX stock price reached its highest trading level at $738.87 during the session, while it also had its lowest trading level at $724.74.
Ratios:
For a deeper understanding of Idexx Laboratories, Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 278.46 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 60.16. For the most recent quarter (mrq), Quick Ratio is recorded 0.81 and its Current Ratio is at 1.12. In the meantime, Its Debt-to-Equity ratio is 0.71 whereas as Long-Term Debt/Eq ratio is at 0.31.
On October 01, 2025, UBS started tracking the stock assigning a Neutral rating and target price of $720.
BTIG Research reiterated its Buy rating for the stock on August 05, 2025, while the target price for the stock was revised from $545 to $785.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 07 ’25 when Hunt Nimrata sold 9,425 shares for $703.34 per share. The transaction valued at 6,629,014 led to the insider holds 21,149 shares of the business.
NIMRATA K HUNT bought 9,425 shares of IDXX for $6,629,060 on Nov 07 ’25. On Aug 22 ’25, another insider, SZOSTAK M ANNE, who serves as the Director of the company, sold 2,187 shares for $647.33 each. As a result, the insider received 1,415,700 and left with 262 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IDXX now has a Market Capitalization of 58077806592 and an Enterprise Value of 58871271424. As of this moment, Idexx’s Price-to-Earnings (P/E) ratio for their current fiscal year is 57.55, and their Forward P/E ratio for the next fiscal year is 50.25. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.72. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.91 while its Price-to-Book (P/B) ratio in mrq is 37.20. Its current Enterprise Value per Revenue stands at 14.127 whereas that against EBITDA is 40.96.
Stock Price History:
The Beta on a monthly basis for IDXX is 1.66, which has changed by 0.71402836 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, IDXX has reached a high of $769.98, while it has fallen to a 52-week low of $356.14. The 50-Day Moving Average of the stock is 8.39%, while the 200-Day Moving Average is calculated to be 30.39%.
Shares Statistics:
For the past three months, IDXX has traded an average of 512.23K shares per day and 750140 over the past ten days. A total of 80.00M shares are outstanding, with a floating share count of 78.97M. Insiders hold about 1.11% of the company’s shares, while institutions hold 92.81% stake in the company. Shares short for IDXX as of 1763078400 were 1698042 with a Short Ratio of 3.32, compared to 1760486400 on 1776269. Therefore, it implies a Short% of Shares Outstanding of 1698042 and a Short% of Float of 2.79.
Earnings Estimates
The stock of Idexx Laboratories, Inc (IDXX) is currently in the spotlight, with 10.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is $3.41, with high estimates of $3.54 and low estimates of $3.28.
Analysts are recommending an EPS of between $13.0 and $12.63 for the fiscal current year, implying an average EPS of $12.9. EPS for the following year is $14.42, with 12.0 analysts recommending between $14.97 and $14.11.
Revenue Estimates
A total of 10 analysts believe the company’s revenue will be $1.07B this quarter.It ranges from a high estimate of $1.08B to a low estimate of $1.07B. As of. The current estimate, Idexx Laboratories, Inc’s year-ago sales were $954.29MFor the next quarter, 10 analysts are estimating revenue of $1.1B. There is a high estimate of $1.13B for the next quarter, whereas the lowest estimate is $1.08B.
A total of 13 analysts have provided revenue estimates for IDXX’s current fiscal year. The highest revenue estimate was $4.29B, while the lowest revenue estimate was $4.28B, resulting in an average revenue estimate of $4.29B. In the same quarter a year ago, actual revenue was $3.9BBased on 13 analysts’ estimates, the company’s revenue will be $4.66B in the next fiscal year. The high estimate is $4.72B and the low estimate is $4.62B.
